tbuckley/cabot-search huggingface dataset:
AB0950 Is There a Relation Between Neuropathic Pain and Electrophysiologic Findings in Carpal Tunnel?: Table 1.
Authors: T. Dandinoglu, M. Karadeniz, V. Yılmaz, Ö. Dandin, U. Teomete
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Carpal tunnel syndrome (CTS) is the most common and well-described compression neuropathy of the upper limb. Scales like DN4 (Douleur Neuropathique 4) and LANSS (Leeds Assessment of Neuropathic Symptoms and Signs) are frequently used to determine pain mechanism (neuropathic and/or nociceptive). To the best of our knowledge, there is no existing study investigating neuropathic complaints and it9s relation between electrophysiologic changes after single local steroid injection in CTS. <h3>Objectives</h3> We tried to find out if there is a relationship between DN4/LANSS score changes and electrophysiologic changes after single local steroid injection. <h3>Methods</h3> 41 participants diagnosed clinically and electrophysiologically with idiopathic CTS between the ages of 20-65 years were included in the study. LANSS and DN4 neuropathic pain scales were used to identify neuropathic pain and patients with neuropathic complaints (DN4 ≥4 and LANSS ≥12) were received local steroid injection into the carpal tunnel. Tests were repeated 2 months after the injection. <h3>Results</h3> When compared to pre-treatment results a moderate correlation was observed between SNAP (Sensory Nerve Axon Potential) changes and DN4 scores (p&lt;0.05, r: 0.340) in this study (Table 1). We think due to ineffectiveness of routine nerve conduction studies on evaluating thin nerve fibers, no further relationship was observed and relation between DN4 and SNAP may be related to sensitization of thick myelinated A-beta nerve fibers which physiologically supply fine touch, vibration and position sense and can be evaluated with routine nerve conduction studies. <h3>Conclusions</h3> Additional studies are needed to explain the contribution of thick myelinated fiber dysfunction to pain mechanisms and these complex findings in CTS. <h3>Disclosure of Interest</h3> None declared
The Effect of Purines, Nucleosides, and Nucleotides on the Carcinostatic Action of 8-Azaguanine&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: Alfred Gellhorn, Erich Hirschberg, Alice Kells
Journal: JNCI Journal of the National Cancer Institute (1954)

The Effect of Purines, Nucleosides, and Nucleotides on the Carcinostatic Action of 8-Azaguanine Get access Alfred Gellhorn, Alfred Gellhorn Departments of Medicine and Biochemistry and the Institute of Cancer Research, College of Physicians and Surgeons, Columbia University, N. Y. Search for other works by this author on: Oxford Academic PubMed Google Scholar Erich Hirschberg, Erich Hirschberg Departments of Medicine and Biochemistry and the Institute of Cancer Research, College of Physicians and Surgeons, Columbia University, N. Y. Search for other works by this author on: Oxford Academic PubMed Google Scholar Alice Kells Alice Kells Departments of Medicine and Biochemistry and the Institute of Cancer Research, College of Physicians and Surgeons, Columbia University, N. Y. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 14, Issue 4, February 1954, Pages 935–939, https://doi.org/10.1093/jnci/14.4.935 Published: 01 February 1954 Article history Received: 09 October 1953 Published: 01 February 1954
ANAPHYLACTIC REACTIONS TO TETRACYCLINE
Authors: F A KINGERY
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Potentiation of Doxorubicin Cytotoxicity by (+)-1,2-Bis-(3,5-dioxopiperazin-l-yl) Propane (ICRF-187) in Human Leukemic HL-60 Cells
Authors: E Monti, B K Sinha
Journal: Cancer Communications (1990)

The bisdioxopiperazine propane, ICRF-187, has been reported to potentiate doxorubicin cytotoxicity in certain tumor cell lines; however, the mechanism of this interaction is not known. In order to define the mechanism of this interaction, we examined the effects of ICRF-187 on doxorubicin cytotoxicity, free radical formation, and drug accumulation in human leukemia HL-60 cells. Studies show that ICRF-187 synergistically potentiated doxorubicin cytotoxicity in HL-60 cells. This potentiation of doxorubicin cytotoxicity by ICRF-187 appeared to result from enhanced drug dependent free radical formation without effecting doxorubicin uptake in HL-60 cells.
Community alternatives to institutional care
Authors: L D Ozarin
Journal: American Journal of Psychiatry (1976)

The Community Mental Health Center Amendments of 1975 (Public Law 94-63) mandate that federally funded mental health centers provide specific services to patients discharged from mental health facilities, including follow-up care and a system of transitional halfway houses. In addition, they must provide assistance in screening potential inpatients and provide alternative treatment when appropriate. The author stresses the need to coordinate the resources of public and private agencies through interagency planning, collaboration, and coordinated service delivery, the need to create new resources where none exist, and the need for more involvement by psychiatristis.
PTU-305 Interventions to improve patient safety and quality of care relating to ascitic drain management
Authors: J Hawken, S Sumanasuriya, A Gera
Journal: Gut (2015)

<h3>Introduction</h3> Large volume ascites is a common cause of hospitalisation and and has a two-year mortality of approximately 50%. Therapeutic paracentesis is the first line treatment for patients with large or refractory ascites and is regularly carried out in medical wards and radiology departments. Paracentesis is generally a safe procedure but there are variations in practice and potential complications, so an audit was carried out comparing local practice to recommendations set out by the British Society of Gastroenterology. A small group of junior doctors devised and implemented a number of interventions, after which the audit loop was completed to gauge their impact. <h3>Method</h3> A retrospective study was carried out looking at ascitic drain insertions at Queen Elizabeth district general hospital over the three month period up to 31/3/2014. Reason for insertion, documentation of consent, consideration of complications, use of ultrasound, insertion site, vessels used for specimen collection, prescription of plasma expanders and total drainage time were recorded. A number of interventions were devised, including a sticker to put in patient notes to improve documentation and act as a reminder of best practice. A trust guideline was established and multidisciplinary teaching sessions were held for doctors and nurses. A re-audit then evaluated drain insertions over three months up until 31/7/14. <h3>Results</h3> 35 drain insertions were evaluated in total (mean age 58), 80% &gt;wards and 20% &gt;interventional radiology. Cirrhosis was the most common cause of cirrhosis (60%), followed by malignancy (37%). Documentation of consent rose from 47% pre-intervention to 86%, while documentated consideration of complications rose from 33% to 79%. Clear instructions relating to drain removal time went from 62% to 100%. Following the interventions, there was also more consistency with the presciption of plasma plasma expanders and improved rates of ascitic fluid inoculation into blood culture bottles. <h3>Conclusion</h3> Simple interventions of improved resources, more readily accessible information and multidisciplinary teaching can lead to better documentation and reduction in risk of complications. Care can be made more consistent and aligned with national recommendations. By identifying areas for improvement and taking on contained projects with clear goals, junior staff are capable of making small, precise interventions to a service that can lead to gains in quality and safety of care. <h3>Disclosure of interest</h3> None Declared. <h3>References</h3> Gines P, <i>et al</i>. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987;7:12–18 Lucena MI, <i>et al</i>. Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. Eur J Clin Pharmacol. 2002;58:435–440 Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut 2006;55;1–12
THU0294 Thromboangeitis Obliterans: Efficacy of Bosentan in the Treatment of Digital Ulcers
Authors: P.E. Agueda, O. Alejandro, B. Helena, A. Eulalia, R.M. Samantha, S. Juana, N. Joan Miquel, N. Javier
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Thromboangeitis obliterans (TOA) was described by Leo Buerguer in 1908. It is an occlusive vasculitis which is associated to licit habits such as smoking. Treatment consists of smoking cessation. Patients require ample support with pain medications and vasodilators. Amputation often occurs during the course of the disease. <h3>Objectives</h3> To evaluate the efficacy and safety of Bosentan in the treatment of digital ulcers in the course of TOA. <h3>Methods</h3> Retrospective study of patients with TOA treated with Bosentan. All patients fulfilled the criteria proposed by Olin (Curr Opin Rheumatol 2006;18:18-24). All patients were having digital ulcers refractory to conventional treatments. An arteriography confirming the vasculopathy was mandatory. All patients were treated previously with Alprodastil during 21 days. Cessation of smoking was required to all patients. Bosentan was used as compassionate use (off-label). The starting dose was in all cases 62.5 mg/day/po during the firs month, followed – if tolerated – by an increase up to 125 mg/12/po. <h3>Results</h3> Six patients were recruited, 4 males and 2 females; mean age 49 years (range 60-39). The duration of treatment with bosentan was 12.6 months (range 11-16). All patients healed their ulcers except one that required partial amputation of the tip of the finger because of osteomyelitis. In 5 patients treatment with Bosentan was interrupted because of an excellent evolution with a complete healing of their ulcers. Follow up after interruption: 18.4 months (10-24). There was no recurrence of digital ulcers. Bosentan was well tolerated with absence of adverse reactions. <h3>Conclusions</h3> Bosentan might be effective in the treatment of digital ulcers in the course of Thromboangeitis obliterans. Prospective randomized trials would be welcome to confirm the utility of this drug in the treatment of digital ulcers. <h3>Disclosure of Interest</h3> None declared
Primary Malignant Lymphoma of the Esophagus
Authors: T. Doki, S. Hamada, H. Murayama, H. Suenaga, Y. Sannohe
Journal: Endoscopy (1984)

We report a rare case of primary malignant lymphoma of the esophagus. The 45-year-old patient was followed up radiologically and endoscopically for 3 months prior to operation.
Expression of Somatostatin Receptor Type 2A and PTEN in Neuroendocrine Neoplasms Is Associated with Tumor Grade but Not with Site of Origin
Authors: Hideo Wada, Katsuya Matsuda, Yuko Akazawa, Yuka Yamaguchi, Shiro Miura, Nozomi Ueki, Akira Kinoshita, Koh-ichiro Yoshiura, Hisayoshi Kondo, Masahiro Ito, Takeshi Nagayasu, Masahiro Nakashima
Journal: Endocrine Pathology (2016)
Five-Year Results of Neoadjuvant Cisplatin, Methotrexate and Vinblastine Chemotherapy plus Radical Cystectomy in Locally Advanced Bladder Cancer
Authors: Vincenzo Scattoni, Luigi Da Pozzo, Luciano Nava, Luigi Broglia, Galli Laura, Tullio Torelli, Biagio Campo, Massimo Maffezzini, Patrizio Rigatti
Journal: European Urology (1995)
Correction: Propranolol and Thyroid Storm
Authors: SN Markovic, DJ Inwards, RP Phyliky
Journal: Annals of Internal Medicine (2000)

Corrections21 November 2000Correction: Propranolol and Thyroid StormFREESearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-10-200011210-00026 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In a letter to the editor on propranolol and thyroid storm (1), the dobutamine dose given should be 12 µg/kg of body weight per minute, not 12 g/kg of body weight.Reference1. Ashikaga H, Abreu R, Schneider RF. Propranolol administration in a patient with thyroid storm [Letter]. Ann Intern Med. 2000;132:681-2. LinkGoogle Scholar Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPropanolol Administration in a Patient with Thyroid Storm Hiroshi Ashikaga , Ricardo Abreu , and Roslyn F. Schneider Metrics 21 November 2000Volume 133, Issue 10Page: 839KeywordsBody weightStormsThyroid ePublished: 21 November 2000 Issue Published: 21 November 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
OP0200 Global DNA Methylation Patterns Differ Between Responders and Non-Responders in Psoriatic Arthritis Patients Treated with Tumor Necrosis Factor-α Inhibitors
Authors: D.D. O'Rielly, Y. Zhang, D. Codner, A. Dohey, A. Zhou, N. Al Ghanim, S. Hamilton, G. Zhai, P. Rahman
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Although tumor necrosis factor-α inhibitors TNFi are well established treatment for psoriatic arthritis (PsA), the efficacy can vary greatly between patients. In this study, we examined the genome-wide epigenetic changes among TNFi responders and TNFi secondary failures in PsA patients <h3>Methods</h3> Twenty-one PsA patients (15 males; 6 females) were considered TNFi responders of which 13 were treated with etanercept and 8 with adalumimab. The median follow up duration was 18 months. Twenty patients (5 males; 15 females) were secondary TNFi failures of which 15 were treated with etanercept and 5 with adalumimab. The median follow up duration was 36 months. Genome-wide DNA methylation profiling was performed using the Illumina HumanMethylation450k Beadchip, which measures ∼480,000 different CpG sites per sample and covers 96% of RefSeq genes. The methylation level at each CpG site was measured by β values varying from 0 (no methylation) to 1 (100% methylation). Analysis was performed using a t-test after a Bonferroni-Holm correction was applied. Regions of interest were selected based on β value (β diff&gt;5%) and p-value (p&lt;0.01). <h3>Results</h3> After quality control filtering, 384,599 and 368,863 CpG sites were evaluated for TNFi responders and TNFi failures, respectively. Analysis revealed 72 and 91 CpG sites of interest in the TNFi responder group and in the TNFi failure group, respectively. Top gene candidates for TNFi responders included <i>TRAPPC9</i> (β diff=0.056; p=3.42x10<sup>-6</sup> - functions as an activator of NFkB); <i>CCR6</i> (β diff=0.053; p=0.0028 - regulates the migration and recruitment of dentritic and T cells); and <i>PSORSC13</i> (β diff=0.035; p=0.003). Top candidate genes for TNFi secondary failures included <i>CD70</i> (encoded protein is a ligand for TNFRSF27/CD27), and <i>TNFRSF1B</i> (a member of the TNF receptor superfamily, that mediates most of the metabolic effects of TNFα). <h3>Conclusions</h3> These preliminary results demonstrate that the global DNA methylation pattern differs between TNFi responders and secondary failures. They also serve to highlight the possible importance of epigenetic (methylation) changes with respect to the TNFα signaling pathway. High priority candidate regions and genes identified in this study warrant further validation. <h3>Disclosure of Interest</h3> None declared
Behavioral desensitization of phobic anxiety using thiopental sodium
Authors: T Pearlman
Journal: American Journal of Psychiatry (1980)

The author evaluated a random sample of 25 patients suffering from a variety of phobic anxiety states who were treated with desensitization using thiopental sodium combined with progressive reduction in the use of oral anxiolytic medication. At 24-week follow-up, 11 of the patients reported mild symptoms of phobic anxiety and 14 reported none; 9 of the patients reported their use of tranquilizers had decreased and 15 reported they had used non for at least 2 weeks. These results demonstrate the usefulness of the treatment in producing sustained reduction of phobic anxiety and tranquilizer use.
VOLUNTARY MULTIPLE HEALTH TESTS
Authors: L M PETRIE, C D BOWDOIN, C J McLOUGHLIN
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hyperparathyroidism after Renal Transplantation
Authors: D S David
Journal: New England Journal of Medicine (1969)

Acetylator capacity was determined in two groups of patients who had received procainamide for more than three months.In seven patients antinuclear antibodies (A.N.A.) were detected during treatment, and these changes disappeared (in six patients) or were less pro- nounced (one patient) after withdrawal of the drug.These patients tended to have faster acetylation rates, and five were phenotypically "rapid" acetylators.Five patients who did not develop A.N.A. during treatment had less rapid (P <0 05) rates of acetylation, and four were "slow" acetylators.We suggest that the immuno- logical changes which may occur during procainamide treatment may be associated with the acetylated metabo- lite of procainamide rather than the parent compound and that it might be possible to identify patients at risk.
Progress in Insurance Claim Forms
Authors: H J WETSTONE, M S HONEYMAN, R B MCCOMB
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Recovery Of Natural Killer Cells and Monocyte Subsets Following Autologous Peripheral Blood Stem Cell Transplantation Predicts Longer Progression Free Survival Among Multiple Myeloma Patients
Authors: Natalie S Callander, Paul J Rathouz, Fotis Asimakopoulos, Mark B Juckett, Christopher L Coe, Dagna Sheerar, Karen Ersland, Peiman Hematti, Erin S Costanzo
Journal: Blood (2013)
Central Nervous System metastastasis in gastric or gastro-esophageal junction cancer, correlation with human epidermal growth factor 2 (HER-2) status
Authors: P. Mordenti, P. Seghini, C. Di Nunzio, E. Michieletti, E.M. Stroppa, A. Zangrandi, L. Cavanna
Journal: Annals of Oncology (2015)
Unilateral diaphragmatic crus uptake on FDG positron emission tomographic imaging.
Authors: EUGENE LIN, RAJESH BHOLA
Journal: Clinical Nuclear Medicine (2001)

From the Division of Nuclear Medicine, University of Colorado Health Sciences Center, Denver, Colorado Received for publication July 26, 2000. Accepted August 24, 2000. Reprint requests: Eugene C. Lin, M.D., Department of Radiology, University Hospital, Box A-034, 4200 East Ninth Avenue, Denver, Colorado 80262. E-mail: [email protected]
Quantitative magnetic resonance imaging and the severity of dementia in Alzheimer's disease
Authors: W Bondareff, J Raval, P M Colletti, D L Hauser
Journal: American Journal of Psychiatry (1988)

The T2 component of the magnetic resonance imaging (MRI) signal was measured in 11 brain loci in six elderly patients diagnosed as having probable Alzheimer's disease. T2 values and relative amount of periventricular high-intensity foci were significantly correlated with dementia severity, indicated by the Blessed-Roth Dementia Scale score. Although the mean T2 value for left hemispheric structures was more closely correlated with the dementia score, T2 values did not differ significantly in the right and left hemispheres or in gray and white matter. These findings suggest that more severe dementia in Alzheimer's disease is associated with more water in the brain.